huskers123

huskers123
Send Message
View as an RSS Feed
  • What Stocks To Avoid Early In 2016  [View instapost]
    Hi Bret, good article as always. How does the Fed play into biotechs. They seem H-bent on raising rates. In the past biotechs haven't faired well when rates rise.
    Jan 16, 2016. 06:31 AM | Likes Like |Link to Comment
  • Solithromycin From Cempra Is Positioning To Be The Treatment Of Choice For CABP  [View article]
    Wife works for HMO as someone that participates in deciding on what they will include \ exclude on their prescription coverage's. I asked her what would be the chances it wouldn't be included at $200 with cheaper alternatives, but severe side effects...and went on to list the side effects. She says HMO's, and she's work for several of the largest ones, are (believe it or not) seeking the best patient outcome over course of treatment to end result accounting for potential side effects. Basically, said Soli would be looked on favorably in her opinion.
    Nov 29, 2015. 04:40 PM | 1 Like Like |Link to Comment
  • Solithromycin From Cempra Is Positioning To Be The Treatment Of Choice For CABP  [View article]
    With those side effects, sounds more expensive than $200 for Soli with no serious side effects. Won't be a difficult choice for a Dr. to chose which drug to prescribe.
    Nov 29, 2015. 11:20 AM | Likes Like |Link to Comment
  • Solithromycin From Cempra Is Positioning To Be The Treatment Of Choice For CABP  [View article]
    I wondered as well if this was a coordinated take down. The analyst's really got it wrong, but if you look at their expertise...they are probably not all that qualified to assess Soli's value. The SunTrust analyst comes the close in having the background, credentials. Even the CEO mentioned that Pharma's don't have anti-biotic/anti-infla... expertise to assess value on data alone, but a few. At some point pulmonary and pediatrics' will come into their valuation models, of which a few analysts only have CABP in their models. To compare Soli with Moxi as an equal choice for doctors to prescribe by some analysts, is pure incompetence. Soli will no doubt be the first line treatment for CABP. By 2017, it could be the only choice given further resistance on current antibiotics', and coming new restrictions on Fluor's. and The PPS should be at new highs, which I believe it will get their as the market comes to a realization that the IV trial was indeed a huge success.
    Nov 29, 2015. 11:16 AM | Likes Like |Link to Comment
  • The Commodity Collapse Continues  [View instapost]
    I've been waiting for gold to hit in the $600-$700 range. Load up then. One thing you can count on is the Fed making the wrong move at the wrong time. Raising interests rates now, and future is and will put tremendous pressure on commodities, emerging markets.
    Nov 29, 2015. 10:27 AM | 1 Like Like |Link to Comment
  • Cellceutix: Small Biotech With High Risk / High Reward Profile  [View article]
    Your broker won't let you short OTC stocks. Give me a break Mako.
    Sep 4, 2015. 08:52 PM | Likes Like |Link to Comment
  • Cellceutix: Small Biotech With High Risk / High Reward Profile  [View article]
    Obviously he has been always short, maybe he is a shark we all know about that wrote a recent article. You can't be a DR. and read Mako's article and say it somehow enlighten you. If he was a Dr. he'd know that there were so many holes in that article. I still haven't found anything in it that had any merit.
    Sep 4, 2015. 08:46 PM | Likes Like |Link to Comment
  • A Professional Fight :The Shorts Vs Cellceutix  [View instapost]
    They seem to get others to pay most of the costs of the trials,like Dana Faber. With Purisol that's not the Case. Good take on the fighter analogy. CTIX got hit with a left hooked,but will Counter with 5 trials, B-OM, B Phase III,Kevetrin, Kevtrin combo, Purisol...all above the belt. LOL.
    Aug 20, 2015. 09:50 PM | Likes Like |Link to Comment
  • Cellceutix: Small Biotech With High Risk / High Reward Profile  [View article]
    We traded over 1.1 million shares today...perhaps capitulation.
    Aug 19, 2015. 04:44 PM | 1 Like Like |Link to Comment
  • Cellceutix: Empty Office, Unviable 'Science', Misleading Disclosures, 96% Downside  [View article]
    Hanging on to that administrative error. Nothing else in your article has been shown to be true. Has it now Mako or Dr Ten Bagger are you one in the same?
    Aug 18, 2015. 05:15 PM | 1 Like Like |Link to Comment
  • Cellceutix: Small Biotech With High Risk / High Reward Profile  [View article]
    Matija, I'd be interested after the 11 Cohort data is released and your assessment. Also what would be the potential of the drug for OC. Thanks!
    Aug 17, 2015. 01:41 PM | 1 Like Like |Link to Comment
  • Cellceutix: Empty Office, Unviable 'Science', Misleading Disclosures, 96% Downside  [View article]
    They approve the design of the trial. A Company can move forward without the FDA's input no the trial design, but that usually doesn't end up to well.
    Aug 17, 2015. 09:08 AM | 2 Likes Like |Link to Comment
  • $CTIX - My Visit To Cellceutix, The Biotech That A Short Seller Recently Called A Sham  [View instapost]
    Hi Karin. Short and Sweat, but further concludes on the slanderous SA article with nothing that I could find was true after all the rebuttals. It's dis-hearting that people will go to no length to make $, no matter how unethical. I hope for the best for CTIX and success, mainly for the potential of their drugs and how they can help people with serious heath diseases, $$$'s come second.

    I do believe CTIX is getting far enough along with the progress of the pipeline, that these type of "Hit" articles will be in the past.
    Aug 15, 2015. 06:29 PM | 2 Likes Like |Link to Comment
  • Cellceutix: Small Biotech With High Risk / High Reward Profile  [View article]
    There actually is an SA article in 2013 or 2012 that had CTIX at $100 if their pipeline came in successfully.
    Aug 15, 2015. 06:06 PM | 2 Likes Like |Link to Comment
  • Cellceutix: Empty Office, Unviable 'Science', Misleading Disclosures, 96% Downside  [View article]
    UNEMON1, your a little behind on the discussion.
    Aug 15, 2015. 06:02 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
96 Comments
222 Likes